

**STABILIS PHARMA INC.**  
**BALANCE SHEET AS AT MARCH 31, 2020**

		Amount in USD 31-Mar-20	Amount in USD 31-Mar-19
<b>A ASSETS</b>			
<b>I Current assets</b>			
(a) Financial assets			
(i) Cash and cash equivalents	1	1,519	1,819
(ii) Other financial assets	2	2,877	2,877
<b>Total current assets</b>		<b>4,396</b>	<b>4,696</b>
<b>TOTAL ASSETS</b>		<b>4,396</b>	<b>4,696</b>
<b>B EQUITY AND LIABILITIES</b>			
<b>I Equity</b>			
(a) Equity share capital	3	1,000	1,000
(b) Other equity	4	864	1,164
<b>Total Equity</b>		<b>1,864</b>	<b>2,164</b>
<b>II Liabilities</b>			
<b>1 Current liabilities</b>			
(a) Financial liabilities			
(ii) Other financial liabilities	5	2,533	2,533
<b>Total current liabilities</b>		<b>2,533</b>	<b>2,533</b>
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>4,396</b>	<b>4,696</b>

**STABILIS PHARMA INC.**  
**STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2020**

Particulars	Note No.	Amount in USD	Amount in USD
		31-Mar-20	31-Mar-19
1 Revenue from operations		-	-
2 Other Income		-	-
<b>3 Total Revenue (1+2)</b>		<u>-</u>	<u>-</u>
<b>4 Expenses</b>			
(a) Finance costs	6	300	300
(b) Other expenses	7	-	(2,500)
<b>Total expenses</b>		<u>300</u>	<u>(2,200)</u>
<b>5 Profit / (Loss) before exceptional items and taxes (3-4)</b>		<u>(300)</u>	<u>2,200</u>
6 Exceptional Item		-	-
<b>7 Profit / (Loss) before taxes (5+6)</b>		<u>(300)</u>	<u>2,200</u>
<b>8 Tax Expense:</b>			
(1) Current tax		-	1,558
(2) Deferred tax		-	-
Total tax expenses		<u>-</u>	<u>1,558</u>
<b>VII Profit / (Loss) for the year after tax</b>		<u>(300)</u>	<u>643</u>

STABILIS PHARMA INC.  
STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED MARCH 31, 2020

(A) Equity share capital

Particulars	Amount in USD
Balance as at March 31, 2018	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2019	1,000
Changes in equity share capital during the year	-
Balance as at March 31, 2020	1,000

(B) Other equity

Particulars	Share application money pending allotment	Reserves and surplus	Items of other comprehensive income	Total
		Retained earnings	Re -measurement of the defined benefit liabilities / (assets)	
Balance as at March 31, 2018	-	521	-	521
Profit/loss for the year		643		643
Balance as at March 31, 2019	-	1,164	-	1,164
Profit/loss for the year		(300)		(300)
Balance as at March 31, 2020	-	864	-	864

## STABILIS PHARMA INC.

## Notes forming part of financial statement

## Note

## No.

		Amount in USD	
1	Cash and cash equivalents	31-Mar-20	31-Mar-19
	Particulars		
	Balances with banks:		
	In current accounts	1,519	1,819
	<b>Total</b>	<b>1,519</b>	<b>1,819</b>
2	Other financial assets	31-Mar-20	31-Mar-19
	Particulars		
	Advances to related parties	2,877	2,877
	<b>Total</b>	<b>2,877</b>	<b>2,877</b>
3	Share capital	31-Mar-20	31-Mar-19
	Particulars		
	<b>Issued, subscribed and fully paid-up</b>		
	Equity share capital	1,000	1,000
	<b>Total</b>	<b>1,000</b>	<b>1,000</b>
4	Reserves and surplus	31-Mar-20	31-Mar-19
	Particulars		
	<b>Surplus in statement of profit and loss</b>		
	Opening balance	1,164	521
	Add: Profit / (Loss) for the year	(300)	643
	<b>Closing balance</b>	<b>864</b>	<b>1,164</b>
	<b>Total</b>	<b>864</b>	<b>1,164</b>
5	Other Current financial Liabilities	31-Mar-20	31-Mar-19
	Particulars		
	Payable to group entities	2,533	2,533
	<b>Total</b>	<b>2,533</b>	<b>2,533</b>

**STABILIS PHARMA INC.**  
**Notes forming part of financial statement**

**Note**

**No.**

6	Finance cost	Amount in USD	
		31-Mar-20	31-Mar-19
	<b>Particulars</b>		
	Bank charges	300	300
	<b>Total</b>	<b>300</b>	<b>300</b>

7	Other expenses	Amount in USD	
		31-Mar-20	31-Mar-19
	<b>Particulars</b>		
	Payment to Auditors - For Statutory Audit	-	(2,500)
	<b>Total</b>	<b>-</b>	<b>(2,500)</b>